Tuberculosis treatment intermittency in the continuation phase and mortality in HIV-positive persons receiving antiretroviral therapy

Table 2 Survival Analysis. Multivariable Cox Proportional Hazards Models

Covariate	Not stratified by study site			Stratified by study site
Covariate	HR	95% CI	P value	HR	95% CI	P value
Continuation phase frequency
2–3/week (ref)	1.00	–	0.02	1.00		0.97
5–7/week	0.71	0.52, 0.96	0.02	1.01	0.62, 1.63	0.97
Age at TB diagnosis (years)			0.02			0.01
30	1.08	0.97, 1.19		1.07	0.97, 1.19
35 (ref)	1.00			1.00
40	1.07	0.90, 1.26		1.07	0.90, 1.27
45	1.21	0.92, 1.57		1.22	0.93, 1.59
50	1.37	1.03, 1.82		1.41	1.06, 1.87
Male sex	0.90	0.70, 1.16	0.41	0.89	0.68, 1.15	0.36
CD4 at TB diagnosis			< 0.001			< 0.001
100	1.25	1.13, 1.39		1.25	1.13, 1.39
150 (ref)	1.00			1.00
200	0.82	0.73, 0.92		0.82	0.73, 0.92
350	0.57	0.42, 0.77		0.56	0.42, 0.76
Site of TB
Pulmonary only	1.00	–	0.48	1.00	–	0.77
Extrapulmonary TB	0.91	0.69, 1.19	0.48	0.96	0.70, 1.30	0.77
ART relative to TB diagnosis
Not on ART	1.00	–	0.05	1.00	–	0.14
On ART	1.28	1.00, 1.63	0.05	1.21	0.94, 1.56	0.14

Analyses were performed both without and with stratification by study site; the latter to account for other potential differences by study site (n = 2288). Missing data were imputed via multiple imputation
ART antiretroviral therapy

ISSN: 1471-2334